View by Specialty

Headline News

View more

FDA approves vutrisiran for ATTR amyloidosis with cardiomyopathy

March 21, 2025
2 min read
Save

FDA approves vutrisiran for ATTR amyloidosis with cardiomyopathy

FDA approves vutrisiran for ATTR amyloidosis with cardiomyopathy

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule transthyretin stabilizer, for the treatment of transthyretin amyloidosis with cardiomyopathy.

View more Headline News
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails

Resources

View more

AI in Medicine

Psychedelics & Alternative Therapies

View more Resources
View more Meeting News
View meeting calendar

Blogs & Columns

View more

Opinions on important issues that affect clinical practice.

Perspective on news and developments that may change your practice.
View more Blogs & Columns